Riskpilot← Back to searchSign inGet full access2N Pharma ApS
APSBankruptCVR 41169303Niels Jernes Vej 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 20201 employees
Revenue 2024
DKK 1,1M
+98% vs 2023
EBITDA margin
-50.1%
-28% vs 2023
Equity ratio
39.6%
Financial strength
Net profit 2024
DKK -396K
-14% vs 2023
| Revenue | DKK 1,1M | +98% |
| EBITDA | DKK -540K | -28% |
| Net profit | DKK -396K | -14% |
| Total assets | DKK 26M | +19% |
| Equity | DKK 10,3M | -4% |
| Employees | 1 | — |
Legal name
2N Pharma ApS
CVR number
41169303
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14. februar 2020
Share capital
DKK 40.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør.
Company purpose
Selskabets formål er at drive virksomhed med forskning, udvikling, kommercialisering, handel og fabrikation af lægemidler og dermed beslægtet virksomhed.
Address
Niels Jernes Vej 10
- Event
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 336 | 1.538 | 2.222 | 543 | 1.077 |
| Staff expenses | -594 | -2.961 | -2.074 | -964 | -1.618 |
| EBITDA | -258 | -1.423 | 148 | -421 | -540 |
| Depreciation & amort. | -3 | -16 | -18 | -18 | -18 |
| EBIT | -261 | -1.440 | 130 | -439 | -558 |
| Net financials | 13 | -57 | -40 | -53 | -46 |
| Profit before tax | -249 | -1.496 | 90 | -492 | -604 |
| Tax | -61 | -1.178 | -180 | -145 | -208 |
| Net profit | -188 | -318 | 270 | -347 | -396 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 10.834 | 16.778 | 19.663 | 21.813 | 26.025 |
| Equity | -148 | 8.863 | 11.048 | 10.701 | 10.305 |
| Long-term debt | 9.963 | 5.750 | 6.029 | 6.505 | 7.126 |
| Short-term debt | 268 | 544 | 460 | 2.331 | 6.138 |
| Total debt | 10.231 | 6.293 | 6.489 | 8.836 | 13.264 |
EBITDA margin
-50.1%
This company
15.8%
Market median
-417% vs market
20202024
Equity ratio
39.6%
This company
38.2%
Market median
+4% vs market
20202024
Return on equity
-3.8%
This company
18.4%
Market median
-121% vs market
20202024
Net profit margin
-36.8%
This company
8.1%
Market median
-554% vs market
20202024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20202024
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-02-14 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NT Founder | Founder | 2020 |
| Former (2) | ||
PB Chief Executive Officer | Chief Executive Officer | 2021 – 2026 |
JD Management | Management | 2020 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Board of Directors | 2021 – 2023 | |
| Chairman | 2021 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
2N Pharma Holding ApS
2N Pharma ApS Board members of 2N Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Preben Bruun-Nyzell | Chief Executive Officer | 0 companies |
| Neurometa Therapeutics AB | Founder | 0 companies |
| Josephus Dirk Vestergaard Nieland | Management | 0 companies |
| John Kemp | Board of Directors | 0 companies |
| Alex Leech | Chairman | 0 companies |